Literature DB >> 2183731

Serologic tests for Lyme disease. Interlaboratory variability.

S W Luger1, E Krauss.   

Abstract

The serologic test for the detection of antibodies to Borrelia burgdorferi is the most frequently used laboratory method for the diagnosis of Lyme disease. However, the insensitivity of the assays and the interlaboratory variability are frequent problems. To determine the extent of this variability, one aliquot of serum from each of nine patients with a history of Lyme disease was sent to nine reference laboratories, including national, university, state, and local hospital laboratories. A second aliquot of the original serum was submitted 2 weeks later. Wide variability among laboratories was observed, ranging from a university laboratory that detected antibody to B burgdorferi (IgG or IgM) in 18 of 18 specimens, to a state laboratory that detected antibody in only 8 of 18 specimens. Detection of IgM specific antibodies showed similar variability (range, 2 to 10 of 18). There were eight instances of a fourfold or greater change in titer between the aliquots sent 2 weeks apart, although only three of these were an increase in titer. These results indicate the need for standardization of the assays and the availability of national reference material. It is recommended that the results of serologic testing should not be relied on as the sole criteria in making the diagnosis of Lyme disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2183731

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  18 in total

1.  Intra- and interlaboratory reproducibility of an ELISA serological test for Lyme disease.

Authors:  M C Tammemagi; J W Frank; M Leblanc; H Artsob
Journal:  Can J Infect Dis       Date:  1995-03

2.  Quality control assessment of Canadian laboratories testing for Lyme disease.

Authors:  H Artsob; M Garvie
Journal:  Can J Infect Dis       Date:  1991

3.  Lyme disease surveillance in California.

Authors:  R Werra
Journal:  West J Med       Date:  1991-02

4.  Interlaboratory comparison of test results for detection of Lyme disease by 516 participants in the Wisconsin State Laboratory of Hygiene/College of American Pathologists Proficiency Testing Program.

Authors:  L L Bakken; S M Callister; P J Wand; R F Schell
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

5.  Detection of anti-Borrelia burgdorferi antibody responses with the borreliacidal antibody test, indirect fluorescent-antibody assay performed by flow cytometry, and western immunoblotting.

Authors:  J R Creson; L C Lim; N J Glowacki; S M Callister; R F Schell
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

6.  Improved serodiagnostic testing for Lyme disease: results of a multicenter serologic evaluation.

Authors:  R B Craven; T J Quan; R E Bailey; R Dattwyler; R W Ryan; L H Sigal; A C Steere; B Sullivan; B J Johnson; D T Dennis; D J Gubler
Journal:  Emerg Infect Dis       Date:  1996 Apr-Jun       Impact factor: 6.883

7.  Differentiation of borreliacidal activity caused by immune serum or antimicrobial agents by flow cytometry.

Authors:  Y F Liu; L C Lim; K Schell; S D Lovrich; S M Callister; R F Schell
Journal:  Clin Diagn Lab Immunol       Date:  1994-03

8.  Evaluation of a passive hemagglutination assay as screening test and of a recombinant immunoblot as confirmatory test for serological diagnosis of Lyme disease.

Authors:  A Hamann-Brand; M Flondor; V Brade
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-07       Impact factor: 3.267

9.  Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo.

Authors:  J Alder; M Mitten; K Jarvis; P Gupta; J Clement
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

10.  Novel Diagnosis of Lyme Disease: Potential for CAM Intervention.

Authors:  Aristo Vojdani; Frank Hebroni; Yaniv Raphael; Jonathan Erde; Bernard Raxlen
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-15       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.